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Abstract: Approximately half of patients started on an oral anticoagulant in the USA now receive 
one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal 
agent for the direct thrombin inhibitor dabigatran, a specific reversal agent for the anti-factor Xa 
(FXa) DOACs has yet to be licensed. Unlike the strategy to reverse the only oral direct thrombin 
inhibitor with idarucizumab, which is a humanized monoclonal antibody fragment, a different 
approach is necessary to design a single agent that can reverse multiple anti-FXa medications. 
Andexanet alfa is a FXa decoy designed to reverse all anticoagulants that act through this 
part of the coagulation cascade including anti-FXa DOACs, such as apixaban, edoxaban and 
rivaroxaban, and indirect FXa inhibitors such as low-molecular-weight heparins. This narrative 
reviews the development of andexanet alfa and explores its basic science, pharmacokinetics/
pharmacodynamics, animal models, and human studies.
Keywords: factor Xa, DOAC, andexanet alfa, reversal, rivaroxaban, apixaban
Introduction
Direct oral anticoagulants (DOACs) are associated with lower rates of fatal bleeding 
and death from major bleeding compared to vitamin K antagonists (VKAs).1–3 All-cause 
mortality is also significantly reduced with DOACs, particularly among patients with 
nonvalvular atrial fibrillation.1,2 However, despite the preponderance of evidence of their 
safety, the absence of specific antidotes against DOACs has discouraged many patients 
and their physicians from embracing their emergence as long overdue alternatives to 
VKAs.4 Instead, the introduction of DOACs was quickly followed by an urgent need 
to develop agents that specifically reverse their anticoagulant effects.
This cautious approach is not surprising since oral anticoagulants have the high-
est rate of emergency room (ER) visits for adverse drug reactions with ~17 visits per 
1,000 individuals per year with almost half resulting in hospitalization.5 Among elderly 
patients, a quarter to a third of all adverse drug reactions seen in the ER are related 
to anticoagulants. Although VKAs such as warfarin are implicated in a vast majority 
of these ER visits in older patients, with the increasing use of DOACs, rivaroxaban is 
now fifth and dabigatran tenth most common.5
Effective reversal strategies have been available for VKAs for decades, initially 
using vitamin K and fresh frozen plasma, and then later on with the addition of 
4-factor prothrombin complex concentrate as the preferred agent for life-threatening 
bleeding.6 For the oral direct thrombin inhibitor, dabigatran, a humanized antibody 
fragment, idarucizumab, was recently developed as its specific antidote and is now 
Correspondence: Scott Kaatz 
Division of Hospital Medicine, Henry 
Ford Hospital, 2799 West Grand 
Boulevard, Detroit, MI 48202, USA 
Tel +1 313 916 8144 
Fax +1 313 916 4460 
Email skaatz1@hfhs.org
Journal name: Journal of Blood Medicine
Article Designation: REVIEW
Year: 2017
Volume: 8
Running head verso: Kaatz et al
Running head recto: Reversing FXa inhibitors
DOI: http://dx.doi.org/10.2147/JBM.S121550
Journal of Blood Medicine 2017:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
142
Kaatz et al
approved for use.7 For oral direct factor Xa (FXa) inhibitors, 
including apixaban, edoxaban, and rivaroxaban, an agent that 
specifically targets these drugs is currently not yet available. 
For this reason, the US Food and Drug Administration (FDA) 
gave a breakthrough and fast track status to the development 
of andexanet alfa, a new investigational drug that binds to 
FXa inhibitors and reverses their anticoagulant effects. Since 
it binds compounds with a high affinity for FXa, it is also 
being evaluated as an antidote against indirect FXa inhibitors, 
such as low-molecular-weight heparin (LMWH), a parenteral 
anticoagulant that has been around for 2 decades and is only 
partially reversed by protamine sulfate.
Structure, preclinical 
trials, pharmacokinetics, 
pharmacodynamics, and 
manufacturing
Andexanet alfa is being developed by Portola Pharmaceu-
ticals and is also known by the brand name Annexa. It is a 
rationally designed, bioengineered, recombinant modified 
protein intended to serve as a universal antidote against direct 
FXa inhibitors and against indirect FXa inhibitors. Scien-
tifically, it has been referred to as PRT064445 or PRT4445, 
and in early medical literature as “r-Antidote”. Andexanet is 
expressed in its mature functional form without the need for 
activation via the intrinsic or extrinsic coagulation pathways.8
Structure and design
To understand andexanet alfa’s action, we briefly review 
the mechanism of action of FXa and FXa inhibitors. FXa 
adheres to the membrane surface along with cofactor Va 
and prothrombin in the presence of calcium to form the 
prothrombinase complex. This assembly of clotting factors 
increases the conversion of prothrombin to thrombin. FXa’s 
N-terminal gamma-carboxyglutamic acid (Gla) domain 
enables it to adhere to surface membranes so that it can 
assemble with factor Va and prothrombin. FXa also has an 
active serine site that cleaves prothrombin to thrombin. The 
indirect FXa inhibitors, including fondaparinux and LMWH, 
conformationally change the structure of antithrombin III 
(ATIII), which makes this natural anticoagulant 1,000-fold 
more effective at blocking the serine active site of FXa and 
prevents conversion of prothrombin to thrombin. The direct 
FXa inhibitors, such as apixaban, betrixaban, edoxaban, and 
rivaroxaban, are small molecules. They directly and reversibly 
block the active serine site of FXa (Figure 1).9
Andexanet alfa is a recombinant modified FXa decoy 
molecule developed as a truncated form of enzymatically 
inactive FXa. The N-residue was retained to minimize the 
risk of immunogenicity.8 Compared to native FXa, struc-
tural modifications were undertaken, including removal of a 
34-residue fragment containing Gla, which lowers the overall 
molecular weight of the compound and shortens the protein. 
This eliminates its potential to bind to membrane surfaces 
and assemble the prothrombinase complex, thus reducing its 
procoagulant potential. The absence of the Gla domain also 
prevents andexanet alfa from taking up space on phospholipid 
surface membranes, thereby allowing native FXa to bind and 
assemble the prothrominase complex. Finally, a mutation at 
the active binding site of andexanet from serine to alanine 
allows it to effectively bind FXa inhibitors, while at the 
same time eliminating its ability to cleave prothrombin and 
generate thrombin. Therefore, andexanet alfa cannot convert 
prothrombin to thrombin because it is unable to bind to phos-
pholipid membrane surfaces and assemble with factor Va and 
prothrombin, and because it cannot convert prothrombin to 
thrombin because of alterations at the cleavage site (Figure 2).
Figure 1 Mechanism of action of r-Antidote.9
Notes: (A) The prothrombinase complex, which consists of factor Xa and 
its cofactor factor Va, assembles on a membrane surface where it converts 
prothrombin (II) to thrombin (IIa). The membrane-binding Gla domain (hatched 
oval) and active site S of factor Xa are essential for factor Xa function. Factor Xa-
directed NOACs bind reversibly to the active site of factor Xa and attenuate its 
capacity to activate II. (B) Fondaparinux, a synthetic pentasaccharide, binds AT and 
catalyzes the inhibition of factor Xa, thus attenuating prothrombin activation. (C) 
r-Antidote, which has its active S converted to A to prevent procoagulant activity, 
binds the NOACs but does not compete with factor Xa for incorporation into 
the prothrombinase complex because it lacks the membrane-binding Gla-domain. 
By binding NOACs, r-Antidote reverses factor Xa inhibition and restores that 
capacity of prothrombinase to generate thrombin and to effect hemostasis. (D) 
r-Antidote competes with factor Xa for fondaparinux-activated antithrombin, 
thereby allowing prothrombinase to generate thrombin. Reprinted with permission 
from  Yeh CH, Fredenburgh JC, Weitz JI. The real decoy: an antidote for factor 
Xa-directed anticoagulants. Circ Res. 2013;113(8):954–957. Available from:http://
circres.ahajournals.org/content/113/8/954.long. Promotional and commercial use 
of the material in print, digital or mobile device format is prohibited without the 
permission from the publisher Wolters Kluwer. Please contact healthpermissions@
wolterskluwer.com for further information.9
Abbreviations: A, alanine; AT, antithrombin; NOACs, new oral anticoagulants; 
S, serine.
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Preclinical trials
In 2008, preclinical studies suggested that andexanet was 
effective in correcting coagulation parameters, such as 
prothrombin time (PT) and the international normalized 
ratio (INR) for apixaban, rivaroxaban, and betrixaban and 
the activated partial thromboplastin time (aPTT) for enoxa-
parin.10 Subsequent in vitro studies showed that andexanet 
effectively reversed enoxaparin and fondaparinux in human 
and rat plasma and in vivo rat models.11,12 In rat models given 
rivaroxaban, andexanet administration effectively reduced 
the free fraction of rivaroxaban. Use of andexanet in mouse 
tail models anticoagulated with aspirin and rivaroxaban 
also decreased anti-FXa activity and reduced blood loss by 
>80% measured 15 minutes after its administration. In rab-
bit liver laceration models anticoagulated with rivaroxaban, 
andexanet reduced blood loss by >85%, corrected both free 
rivaroxaban levels, and reduced anti-FXa by 98%, aPTT 
by 66%, and PT levels by 74%, while recombinant factor 
VIIa, at 150 mg/kg, reduced PT by 85% and aPTT by 54% 
but did not reduce bleeding.13,14 Andexanet alone at the 
highest concentrations tested did not have any effect on PT 
or on a thrombin generation assay that tested FXa activity 
and the effect upon the prothrombinase complex.8 In 2015, 
andexanet also demonstrated the reversal of unfractionated 
heparin (UFH) in human plasma reversing anti-FXa and 
anti-factor IIa while ciraparantag (PER977) had no effect.15 
As expected, protamine also reversed UFH; however, at 
higher doses, it also exhibited strong anticoagulant effects, 
which is an often overlooked adverse effect of protamine use 
in the clinical setting.15 In summary, andexanet corrected 
coagulation assays, restored hemostasis, and reduced blood 
loss in animal models.
Pharmacology, pharmacokinetics, and 
pharmacodynamics
Andexanet is given via the intravenous (IV) route with either 
a 400 mg initial bolus and a 480 mg infusion over 2 hours 
(4 mg/minute) or an 800 mg initial bolus and a 960 mg infu-
sion over 2 hours (8 mg/minute). The drug needs refrigeration 
for storage. Onset is rapid between 2 and 5 minutes. Elimina-
tion half-life appears to be between 30 and 60 minutes. Little 
is known on the elimination (ie, metabolism and excretion) 
of the drug at this point.
Andexanet has high affinity for the FXa inhibitors and 
competes with native FXa to bind the anticoagulants, which 
frees uninhibited FXa to assemble into the prothrombinase 
complex and generate thrombin. Andexanet has a short half-
life and requires a bolus followed by an infusion to allow 
adequate time to achieve a hemostatic plug (Figure 3).16,17 
The Xa inhibitor DOAC serum level rises within a couple of 
hours after administration of andexanet and the drug is not 
“cleared” with the reversal agent, unlike what an antibody 
such as idarucizumab does with dabigatran.17,18
Initially, upon bolus administration, andexanet appears to 
elevate endogenous thrombin potential, although the mecha-
nism is not yet known. However, the compound itself does 
not appear to demonstrate any anticoagulant or procoagulant 
properties. The transient increases in prothrombin fragments 
1 and 2, D-dimer, and thrombin–antithrombin levels may 
be the result of andexanet binding to tissue factor pathway 
inhibitor (TFPI), which is an endogenous inhibitor of FXa .19 
Typically, these transient elevations return to normal within 
1–3 days.17 In theory, andexanet may have potential interac-
tions, such as with circulating ATIII not in the presence of 
heparins, factor V, protein S, protein Z inhibitor, and TFPI, but 
the significance of these interactions requires further study.8
It does not appear that andexanet elicits antibody formation 
against factor X or FXa. While neutralizing antibodies against 
andexanet have not been detected, non-neutralizing antibod-
ies have been detected and typically appear within 30 days 
of andexanet administration. However, antibody titers are 
low suggesting that andexanet has little immunogenicity.16,17 
Patient studies with long-term follow-up, in which andexanet 
is repeatedly administered, are needed to determine if the 
Figure 2 Design of andexanet alfa.
Notes: Serine, the active site of FXa, was substituted with alanine, rendering the molecule unable to cleave and activate prothrombin. The Gla domain of FXa was removed 
to prevent its assembly into the prothrombinase complex, thus removing any anticoagulant effects. Copyright ©2016 Milling TJ Jr, Kaatz S. Preclinical and clinical data for 
factor Xa and “Universal” reversal agents. Am J Med. 2016;129(11s):S80–S88.26
Abbreviations: FXa, factor Xa; Gla, gamma-carboxyglutamic acid.
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S419
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generation of cross-reactive antibodies to native factor X, FXa, 
or andexanet occurs.
Manufacturing concerns
Andexanet is produced from Chinese hamster ovary (CHO) 
cells, and Portola Pharmaceuticals is collaborating with the 
manufacturers CMC Biologics (Copenhagen, Denmark) 
and Lonza (Visp, Switzerland) to provide the recombinant 
protein. One of the FDA’s concerns from their first review 
was the availability of drug once approved, with estimates 
that only 10% of US hospitals could be supplied. Portola 
is working with its manufacturing partners to increase pro-
duction to meet anticipated global needs. As of May 2017, 
andexanet produced from a second manufacturing site, which 
uses a second generation manufacturing process, is undergo-
ing validation and will likely be used in the Annexa-4 study 
(Charles E Mahan, personal communication, from Portola 
Pharmaceuticals 5-25-17).
Early-phase studies
Phase I
In a dose-ranging study, 32 healthy volunteers were random-
ized to receive a single IV bolus dose of placebo or andexanet 
alfa at doses of 30, 90, 300, or 600 mg.20 Blood samples from 
these volunteers were then obtained, mixed with 50  ng/mL of 
rivaroxaban, and then assessed for anti-FXa activity. Andex-
anet alfa reversed anti-FXa activity and restored thrombin 
generation in a dose-dependent manner. No thrombotic 
Figure 3 Time courses of anti-factor Xa activity before and after administration of andexanet.17
Notes: Anti-factor Xa activity among persons who had received anticoagulation treatment with apixaban or rivaroxaban was measured before and after the administration of 
andexanet or placebo on study day 4. Dashed lines indicate the end of administration of the bolus or infusion. (A) Data from participants in the apixaban study (ANNEXA-A) 
who received andexanet, as a 400 mg intravenous bolus, or placebo. (B) Data from participants in the rivaroxaban study (ANNEXA-R) who received andexanet, as an 
800 mg intravenous bolus, or placebo. (C) Data from participants in the apixaban study who received andexanet, as a 400 mg intravenous bolus with a 4 mg/minute infusion 
for 120 minutes, or placebo. (D) Data from participants in the rivaroxaban study who received andexanet, as an 800 mg intravenous bolus with an 8 mg/minute infusion for 
120 minutes, or placebo. Different scales along the x-axis in each graph are used to enable visualization of the immediate, short-term dynamics as well as the longer-term 
dynamics of anti-factor Xa activity after andexanet treatment; the points on the graph represent the mean anti-factor Xa activity level, and I bars indicate the standard error. 
There was a significant difference (P<0.05) in the percent change in anti-factor Xa activity (relative to the pre-bolus activity level) between andexanet and placebo until 2 hours 
after administration of the bolus or infusion. From N Engl J Med., Andexanet alfa for the reversal of factor Xa inhibitor activity.2015;373(25):2413–2424. Copyright © 2015 
Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.17
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events or death occurred. The only serious adverse event was 
pneumonia, which developed in one subject ~3 weeks after 
receiving andexanet. There were three nonserious infusion 
site reactions without anaphylaxis, which occurred in two 
subjects who received 90 mg of andexanet and in one subject 
randomized to placebo.
Phase II
During a series of Phase II clinical trials, healthy adults from 
ages 18 to 45 years were enrolled in randomized, double-
blind, placebo-controlled experiments to assess andexanet’s 
safety and efficacy.19,21–23 On days 1–6, the subjects were 
initially treated to achieve steady state with an FXa inhibitor, 
which could be apixaban, rivaroxaban, betrixaban, edoxaban, 
or enoxaparin. Then, on day 6, they received one of the six 
different dose regimens of andexanet alfa or matched placebo. 
The dose regimens were either IV bolus only or IV bolus 
followed by a continuous infusion.
Across these trials, andexanet alfa was well tolerated. No 
thrombotic, serious, or severe adverse events occurred. Most 
adverse events were mild-to-moderate infusion reactions that 
generally did not require intervention or dose adjustment. 
With regard to immunogenic effect, there were no antibodies 
detected against endogenous human factor X or FXa. How-
ever, ~12% of subjects had low-titer, nonneutralizing antibod-
ies to andexanet alfa.23 Within 2 minutes of administration, 
andexanet alfa demonstrated a dose-dependent reversal of 
the anticoagulant effects of all FXa inhibitors, including 
reduction in anti-FXa activity and restoration of thrombin 
generation and clotting times. Also, following the initial IV 
bolus with continuous infusion of andexanet resulted in a 
sustained reduction of anti-FXa activity, which returned to 
placebo levels ~2 hours after stopping the infusion.
The reduction in anti-FXa activity with andexanet 
directly correlated with the decline in plasma concentrations 
of unbound FXa inhibitor. Subjects who were on apixaban 
5 mg twice daily for 6 days had a 65% decline in anti-FXa 
activity within 2 minutes of receiving 90 mg of andexanet, 
which bound 66% of apixaban in plasma.19 Similarly, those 
who were on rivaroxaban 20 mg daily for 6 days had a 53% 
decline in anti-FXa activity following receipt of 420 mg 
of andexanet, which reduced the plasma concentration of 
unbound rivaroxaban by 51%.24 These results were the basis 
for establishing the 1:1 stoichiometric ratio necessary for 
andexanet to reverse the effect of FXa inhibitors. The optimal 
dose of andexanet required against each FXa inhibitor varied 
and was primarily determined by each drug’s steady state 
plasma concentration and volume of distribution. Therefore, 
in subsequent Phase II trials, the dose of andexanet selected 
for participants on apixaban 5 mg twice daily was 400 mg 
bolus followed by a continuous infusion of 4 mg/minute for 
2 hours, while those who were on rivaroxaban 20 mg daily 
were given an 800 mg bolus followed by a continuous infu-
sion of 8 mg/minute for 2 hours.17,19
Phase III
ANNEXA-A and ANNEXA-R trials
Two trials were conducted to investigate the efficacy and 
safety of andexanet alfa to reverse the anticoagulation effects 
of apixaban and rivaroxaban in healthy older volunteers. 
The ANNEXA trials (andexanet alfa, a novel antidote to the 
anticoagulation effects of FXa inhibitors) were divided into 
the ANNEXA-A arm for apixaban and ANNEXA-R arm 
for rivaroxaban.17 Both were randomized, double blind, and 
placebo controlled. A total of 145 healthy volunteers between 
the ages of 50 and 75 years were randomly assigned (3:1 
ratio for apixaban arm and 2:1 ratio for rivaroxaban arm) to 
receive either andexanet or placebo. Each arm had two parts 
in which participants received IV andexanet bolus only in part 
1 and a continuous 120 minute infusion of andexanet after the 
bolus in part 2. The doses of andexanet were selected based 
on Phase II trials, which determined that the dose of andex-
anet to reverse effects of rivaroxaban is higher compared to 
apixaban due to the higher initial concentration and larger 
volume of distribution of rivaroxaban.
Participants received apixaban 5 mg orally twice a 
day in ANNEXA-A arm for 3.5 days to reach steady-state 
plasma levels. Andexanet bolus of 400 mg was adminis-
tered intravenously 3 hours after the last dose of apixaban 
on day 4 in part 1. The bolus was followed by continuous 
infusion of andexanet at 4 mg/minute for 120 minutes in 
part 2. Anti-FXa activity was significantly reduced after 
andexanet bolus compared to after placebo (mean [± SD] 
reduction, 94±2 vs 21±9%; P<0.001). The reversal of anti-
FXa activity lasted for 2 hours after administration of the 
andexanet bolus and gradually returned to levels seen in the 
placebo group. Andexanet infusion after bolus resulted in 
greater reduction of anti-FXa activity than placebo (92±3 
vs 33±6%, P<0.001). Anti-FXa activity decreased in the 
placebo group at the expected clearance rate of apixaban. 
Reversal of anti-FXa activity persisted for 1–2 hours after 
andexanet bolus and then returned to placebo levels (Figure 
3). All the participants with andexanet had at least 80% 
reversal of anti-FXa activity. None of participants with pla-
cebo had an ≥80% decrease of anti-FXa activity. Andexanet 
also significantly restored thrombin generation compared to 
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placebo (1,323.2±335.4 vs 88.2±125.8 nM minute, P<0.001). 
Thrombin generation increased to levels in the normal range 
in 100% of participants with andexanet and in 11% of par-
ticipants with placebo. Thrombin generation was significantly 
higher in participants who received bolus plus infusion of 
andexanet than in participants with placebo (1,193.1±263.3 
vs 189.4±184.8 nM minute, P<0.001). Thrombin generation 
increased to levels in the normal range in 100% of partici-
pants with andexanet bolus plus infusion, compared to 25% 
of participants with placebo. Unbound apixaban was reduced 
significantly after andexanet bolus compared to placebo (9.3 
vs 1.9 ng/mL, P<0.001). Andexanet bolus plus infusion also 
reduced unbound apixaban significantly compared with 
placebo (6.5 vs 3.0 ng/mL, P<0.001). Unbound apixaban 
increased to placebo levels within 1–3 hours after andexanet 
bolus or infusion.
Participants received rivaroxaban 20 mg orally once a 
day in ANNEXA-R arm for 4 days to reach steady-state 
plasma levels. Andexanet bolus of 800 mg was administered 
intravenously 4 hours after the last dose of rivaroxaban on 
day 4 in part 1. The bolus was followed by continuous infu-
sion of andexanet at 8 mg/minute for 120 minutes in part 
2. Anti-FXa activity reduced significantly after andexanet 
bolus than after placebo (mean [± SD] reduction, 92±11 vs 
18±15%; P<0.001). The reversal of anti-FXa activity lasted 
for 2 hours after administration of the andexanet bolus 
and gradually returned to levels seen in the placebo group. 
Andexanet infusion after bolus resulted in greater reduc-
tion of anti-FXa activity than placebo (97±2 vs 45±12%, 
P<0.001). Anti-FXa activity decreased in the placebo group 
at the expected clearance rate of rivaroxaban. Reversal of anti-
FXa activity persisted for 1–2 hours after andexanet bolus 
and then returned to placebo levels (Figure 3). Andexanet 
also significantly restored thrombin generation  compared 
to placebo (1,314.2±331.2 vs 173.9±104.2 nM minute, 
P<0.001). Thrombin generation increased to levels in the 
normal range in 96% of participants with andexanet and in 
7% of participants with placebo. Thrombin generation was 
significantly higher in participants who received bolus plus 
infusion of andexanet compared with placebo (1,510.4±344.8 
vs 264.4±140.7 nM minute, P<0.001). Thrombin generation 
increased to levels in the normal range in 100% of partici-
pants with andexanet bolus plus infusion and in 0% of partici-
pants with placebo. Unbound rivaroxaban was significantly 
reduced after andexanet bolus compared with placebo (23.4 
vs 4.2 ng/mL, P<0.001). Andexanet bolus plus infusion also 
reduced unbound rivaroxaban significantly compared to pla-
cebo (30.3 vs 12.1 ng/mL, P<0.001). Unbound rivaroxaban 
increased to placebo levels within 1–3 hours after andexanet 
bolus or infusion (Table 1).
Participants were monitored for safety outcomes of throm-
bosis and bleeding for 6 weeks. There were no thrombotic 
events. Antibodies to FXa were not detected in any partici-
pants. Neutralizing antibodies to andexanet were not detected. 
Nonneutralizing antibodies to andexanet were seen in one of 
44 placebo recipients and 17 of 101 andexanet recipients. 
These antibodies disappeared 15–30 days after andexanet, 
suggesting that andexanet has no significant immunogenicity. 
D-dimer and prothrombin fragments were transiently elevated 
but returned to normal range in 24–72 hours.
The ANNEXA-A and ANNEXA-R studies showed that 
andexanet rapidly restores FXa activity and thrombin genera-
tion in participants treated with apixaban and rivaroxaban, 
without serious side effects or clinical thrombosis.
ANNEXA-4 study
ANNEXA-4 (andexanet alfa, a novel antidote to the antico-
agulation effects of FXa inhibitors) is an ongoing  multicenter, 
Table 1 Results from ANNEXA-A and ANNEXA-R trials17
Measures of reversibility of 
apixaban and rivaroxaban
Andexanet after apixaban  
administration (ANNEXA-A)
Andexanet after rivaroxaban  
administration (ANNEXA-R)
ANNEXA-A  
bolus arm 
ANNEXA-A bolus with  
infusion arm
ANNEXA-R  
bolus arm 
ANNEXA-R bolus with  
infusion arm
Bolus Placebo Bolus with  
infusion
Placebo Bolus Placebo Bolus with 
infusion
Placebo
Mean % reduction in anti-factor  
Xa activity
94 21 92 33 92 18 97 45
Mean thrombin generation 
(nM minute)
1,323.2 88.2 1,193.1 189.4 1,314.2 173.9 1,510.4 264.4
Mean reduction in unbound drug 
level (ng/mL)
9.3 1.9 6.5 3 23.4 4.2 30.3 12.1
Note: From N Engl J Med., Andexanet alfa for the reversal of factor Xa inhibitor activity. 2015;373(25):2413–2424. Copyright © 2015 Massachusetts Medical Society. 
Reprinted with permission from Massachusetts Medical Society.17
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prospective, open-label, and single-group study in patients 
with acute life-threatening bleeding while taking an FXa 
inhibitor.16 Patients who need reversal for an urgent proce-
dure or surgery are not evaluated in this study. Patients are 
eligible if they are at least 18 years old and have  received 
any of the four FXa inhibitors, such as apixaban, rivaroxaban, 
edoxaban, and enoxaparin, in the last 18 hours before presen-
tation. Acute major bleeding includes acute life-threatening 
bleeding with signs or symptoms of hemodynamic instability, 
acute bleeding with drop in hemoglobin of at least 2 g/dL or 
hemoglobin level <8 g/dL if no baseline hemoglobin level 
was available, or acute bleeding in a critical organ or area. 
Patients are excluded if surgery is scheduled in <12 hours, 
intracranial hemorrhage in a patient with Glasgow coma 
score <7, intracranial hematoma of ≥60 mL, major throm-
botic event 2 weeks before enrollment, or patients who have 
received dabigatran, VKA, prothrombin complex concen-
trate, or whole plasma in the 7 days before enrollment. A 
total of 67 patients were reported in an interim analysis of 
whom 32 patients received rivaroxaban (median daily dose, 
20 mg), 31 patients received apixaban (median daily dose, 
5 mg), and four patients received enoxaparin. The mean age 
was 77 years, and all had history of thrombotic events and 
cardiovascular disease. Gastrointestinal was the primary 
bleeding site in 33 patients (49%), intracranial in 28 patients 
(42%), and other sites in six patients (9%).
All eligible patients were treated with andexanet before 
anti-FXa levels were known. All patients who received 
andexanet were included in the safety analysis, and patients 
with baseline anti-FXa activity of ≥75 ng/mL (or 0.5 IU/mL 
for patients with enoxaparin) were included in the efficacy 
analysis (47 of 67 patients). The primary outcomes were 
percent change in the anti-FXa activity and rate of excellent 
or good hemostatic efficacy 12 hours after the andexanet 
infusion. Patients received an initial bolus followed by 2-hour 
infusion of andexanet. Bolus dose of 400 mg and total infu-
sion of 480 mg were given if patients received apixaban or 
rivaroxaban >7 hours before andexanet. Dose was increased 
to bolus of 800 mg and total infusion of 960 mg, if patients 
received enoxaparin, edoxaban, or rivaroxaban <7 hours 
before andexanet. Investigators were encouraged to resume 
anticoagulation if clinically indicated. Patient assessments 
were done before the bolus administration (baseline), at the 
end of bolus, at the end of the 2-hour infusion and at 4, 8, 
and 12 hours after infusion was completed, as well as at 3 
and 30 days. Anti-FXa activity and the plasma unbound frac-
tion of FXa inhibitor were measured in this 12-hour period. 
Thrombin generation was measured at baseline, at 8 hours, 
at 12 hours, and on day 3. Patients with intracranial hemor-
rhage were followed with computed tomography or magnetic 
resonance imaging of the head, at baseline, 1 hours, 12 hours, 
and 30 days after the end of infusion. All adverse events, 
including thrombotic events and deaths, were collected dur-
ing the 30-day study period.
Hemostatic efficacy was assessed based on the type of 
bleeding. For intracranial hemorrhage, <20% increase in 
volume at 12 hours was considered excellent hemostasis 
and 20–35% increase in volume at 12 hours was considered 
good hemostasis. Subarachnoid and subdural bleeding was 
assessed similarly but using maximal hematoma thickness. 
For gastrointestinal bleeding, <10% decrease in hemoglobin 
and hematocrit at 12 hours was considered excellent hemo-
stasis and 10–20% decrease in hemoglobin and hematocrit 
at 12 hours was considered good hemostasis. For visible 
bleeding and for musculoskeletal bleeding, cessation of 
bleeding within 1 hour after infusion was considered excel-
lent hemostasis and cessation of bleeding within 4 hours after 
infusion was considered good hemostasis.
In the 26 patients who received rivaroxaban, the median 
anti-FXa activity decreased from 277.0 ng/mL at baseline to 
16.8 ng/mL at the end of andexanet bolus (relative decrease 
[RD], 89%; 95% CI, 58–94), 30.6 ng/mL at the end of andex-
anet infusion (RD, 86%; 95% CI, 55–93), and 177.7 ng/mL 
at 4 hours after infusion (RD, 39%; 95% CI, 27–45). These 
results highlight the mechanism of andexanet and demon-
strate the reversal of Xa inhibition during administration, 
which quickly dissipates once stopped. How this short-term 
reversal affects clinical hemostasis is encouraging with 
the interim analysis of the ANNEXA-4 study, but further 
results are needed. In the 20 patients who received apixa-
ban, the median anti-FXa activity decreased from 149.7 ng/
mL at baseline to 10.3 ng/mL at the end of andexanet bolus 
(RD, 93%; 95% CI, 87–94%) and to 12.5 ng/mL at the end 
of andexanet infusion (RD, 92; 95% CI, 85–94). Anti-FXa 
activity recovered to 103.0 ng/mL at 4 hours after infusion 
(RD, 30%; 95% CI, 23–46) and remained at similar levels at 
8 and 12 hours. In the single patient who received enoxaparin, 
the median anti-FXa activity decreased from 0.61 IU/mL 
at baseline to 0.15 IU/mL at the end of andexanet bolus, 
0.19 IU/mL at the end of andexanet infusion, and 0.46 IU/mL 
at 4 hours after infusion.
Of the 47 patients included in the efficacy analysis, 37 
patients had excellent or good hemostasis (79%; 95% CI, 
64–89), with 31 patients achieving excellent hemostasis and 
six patients achieving good hemostasis 12 hours after the 
andexanet infusion. Nine patients had poor or no hemostatic 
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efficacy, out of which five patients received rivaroxaban and 
four patients received apixaban. Of these patients, three 
patients had gastrointestinal bleeding, four patients had 
intracranial bleeding, and two patients had bleeding at other 
sites. Excellent or good hemostasis was achieved in 84% 
(95% CI, 64–96) of cases with gastrointestinal bleeding and 
in 80% (95% CI, 56–94) of cases with intracranial bleed-
ing. Excellent or good hemostasis was achieved in 81% 
(95% CI, 61–93) of patients who received rivaroxaban and 
in 75% (95% CI, 51–91) of patients who received apixaban. 
Out of five patients with the highest anti-FXa activity after 
andexanet infusion, four patients had received rivaroxaban 
and one patient had received apixaban. All these patients 
achieved excellent or good hemostasis, in spite of receiving 
the lower dose regimen of andexanet. The median anti-FXa 
activity decreased from 487.1 ng/mL at baseline to 327.4 ng/
mL after andexanet infusion.
Among all 67 patients who received andexanet, no one 
experienced an infusion reaction or developed antibodies 
to FXa or X, or neutralizing antibodies to andexanet. In the 
12 patients with thrombotic events, there was one patient 
with myocardial infarction, five patients with strokes, seven 
patients with deep venous thrombosis, and one patient with 
pulmonary embolism. Four of these events occurred within 
3 days after andexanet infusion, whereas the rest occurred 
between 4 and 30 days. A total of 10 deaths (15%) occurred, 
six were cardiovascular in nature and the other four patients 
were noncardiovascular. Anticoagulation was restarted in 18 
patients (27%) within 30 days, but among the 12 patients 
with a thrombotic event, only one patient started therapeutic 
anticoagulation before the event. It is likely that the lack of 
therapeutic anticoagulation rather than a rebound phenom-
enon was responsible for the thrombosis. However, some 
hypothesize that andexanet may block TFPI, which could 
lead to thrombosis.25
The ANNEXA-4 study showed that andexanet bolus and 
infusion result in rapid and significant reversal of anti-FXa 
activity in patients presenting with acute major bleeding 
while on an FXa inhibitor. Excellent or good hemostatic 
efficacy was achieved in 79% of patients and was maintained 
across various subgroups. Clinical hemostatic efficacy was 
sustained hours after andexanet infusion, which suggests that 
prolonged reversal of anti-FXa activity is not necessary for 
good hemostatic effects. There were no serious side effects 
associated with the administration of andexanet; however, 
thrombotic events and deaths were reported. A controlled 
trial is needed to assess whether rates of these events are 
higher than expected for a population that has inherently 
high risk for thrombotic events. ANNEXA-4 is an ongoing 
study, and further analysis after full enrollment may elucidate 
the relationship between reduction in anti-FXa activity and 
hemostatic efficacy.
Summary
Prescribing of DOACs that inhibit FXa is rapidly increasing 
over recent years. Available trial data suggest that even with-
out a readily available reversal agent, DOACs are associated 
with lower major and fatal bleeding rates. However, because 
of growing utilization, the incidence of DOAC-associated 
bleeding has been increasing and is expected to continue to 
rise, therefore, warranting the need for a readily available 
reversal agent. Andexanet alfa is a rationally designed, bio-
engineered FXa decoy. It acts as a competitive inhibitor that 
binds both direct and indirect FXa inhibitors, thereby restor-
ing the ability of native FXa to assemble on phospholipid 
membranes and form the prothrombinase complex. While 
there were initial concerns regarding potential prothrombotic 
properties and immunogenicity, results of early clinical stud-
ies on andexanet have been reassuring. A mutation of the 
active-site binding pocket from serine to alanine eliminates 
the ability for andexanet to cleave prothrombin to thrombin, 
while maintaining its ability to actively bind anticoagulant 
drugs that inhibit FXa. A minority of patients may develop 
low-titer non-neutralizing antibodies to andexanet alfa, 
but these are short lived and become undetectable within 
15–30 days. Andexanet alfa reduces anti-FXa activity by at 
least 80% and achieves excellent or good hemostasis in most 
patients with life-threatening bleeding. The ANNEXA-4 
study is an ongoing trial that will provide further insights 
regarding andexanet’s clinical efficacy as well as the associ-
ated incidence of thrombotic and other adverse events.
Andexanet alfa is being developed as a universal antidote 
for both direct (apixaban, edoxaban, and rivaroxaban) and 
indirect (fondaparinux and LMWH) FXa inhibitors. While 
further data are still necessary to assess adverse outcomes in 
at-risk populations, available results from recent trials have 
been encouraging. Andexanet alfa has the potential to serve 
as a safe and an effective antidote for DOAC-related bleeding.
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